Comparing the outcomes of statins and PCSK9 inhibitors in LDL management in patients with heterozygous familial hypercholesterolemia (HeFH) and diabetes

Background: Aggressive lipid-lowering methods are required for cardiovascular risk management when heterozygous familial hypercholesterolemia (HeFH) is combined with diabetes mellitus. Though statins have been the mainstay of treatment, a viable substitute is the development of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors. Comparative information about their safety and effectiveness in this population is still lacking, though. Aim: This study aims to systematically compare the outcomes of statins and PCSK9 inhibitors in LDL management for patients with HeFH and diabetes. Methodology: A retrospective cohort study was conducted at Hayabad Medical Complex, encompassing 62 individuals with HeFH and diabetes mellitus. Data on demographic characteristics, treatment regimens, LDL-C reduction efficacy, cardiovascular outcomes, safety profile, and patient adherence were analyzed. Results: PCSK9 inhibitors demonstrated superior efficacy in reducing LDL-C levels compared to statins, achieving a mean reduction of 70.9% versus 55.8%, respectively. Moreover, individuals receiving PCSK9 inhibitors experienced a significantly lower incidence of cardiovascular events (2 events vs. 6 events) and reported higher levels of patient satisfaction. Both therapies exhibited a favorable safety profile. Conclusion: Our findings underscore the potential of PCSK9 inhibitors as a preferred therapeutic option over statins in patients with HeFH and diabetes, offering superior LDL-C reduction efficacy, cardiovascular risk reduction, and patient satisfaction. These results highlight the importance of personalized treatment approaches in optimizing cardiovascular risk management.